MedTrace Logo

Efficacy of Targeted Intervention for Topical Steroid Phobia.

NCT03658252 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 270

Last updated 2020-02-26

No results posted yet for this study

Summary

Topical steroids are an important component of treatment for many dermatological conditions, however 'Corticosteroid phobia' is a significant factor contributing to non adherence to prescribed therapy.

The primary aim of this study is to determine the effectiveness of targeted education, and involvement in a moderated social forum in reducing steroid phobia as assessed by the TOPICOP© score. Secondary objectives include determining if a decrease in TOPICOP© score correlates to an increase in compliance, or an improvement in quality of life.

Conditions

  • Dermatologic Disease
  • Phobia
  • Adherence, Medication

Interventions

BEHAVIORAL

Targeted education

Educational video developed by the hospital, addressing common misconceptions of topical steroids. A patient information leaflet on topical steroids

BEHAVIORAL

Online disease specific forum

An invitation to join an online moderated disease specific social forum

Sponsors & Collaborators

  • National University Health System, Singapore

    lead OTHER

Principal Investigators

  • Ellie Choi, MBBS, MRCP, MMed (IM) · National University Healthcare System

  • Chris Tan, MBBS, FAMS · National University Healthcare System

  • Nisha Chandran, MBBS, MRCP, MMed (IM) · National University Healthcare System

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2018-12-31
Completion
2019-05-04

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03658252 on ClinicalTrials.gov